Shanghai Bao Pharmaceuticals

Established in 2019 through strategic restructuring, BaoPharma (02659.HK) is a leader in synthetic biology, focusing on high-barrier, next-generation recombinant proteins and antibody therapeutics. By replacing traditional biochemical extraction with high-efficiency genetic engineering, the company achieves green, large-scale production for niche markets. Center Ventures currently holds a 12% stake in BaoPharma, which successfully listed on the Hong Kong Stock Exchange on December 10, 2025.

Core Product Milestones: 

• SJ02: Recombinant long-acting FSH (Approved and Launched).

• KJ107: Recombinant human hyaluronidase for large-scale subcutaneous delivery (Approved and Launched).

• KJ103: IgG degradase targeted for renal transplant desensitization.